<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04592315</url>
  </required_header>
  <id_info>
    <org_study_id>KB-LP-80-101</org_study_id>
    <nct_id>NCT04592315</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Tolerability and Pharmacokinetics of Lipovirtide in HIV-infected Patients Without Prior Antiviral Therapy</brief_title>
  <official_title>A Study to Assess the Safety, Tolerability and Pharmacokinetics of Lipovirtide in HIV-infected Patients Without Prior Antiviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanxi Kangbao Biological Product Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanxi Kangbao Biological Product Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety, tolerability of single dose lipovirtide injection in HIV-infected&#xD;
      individuals without prior antiviral treatment, and to investigate the pharmacokinetic&#xD;
      characteristics of infected patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 23, 2021</start_date>
  <completion_date type="Anticipated">October 12, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 12, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics：Cmax</measure>
    <time_frame>Day 0 to Day 7</time_frame>
    <description>pharmacokinetic characteristics of Lipovirtide in infected patients：Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics：AUC0-t</measure>
    <time_frame>Day 0 to Day 7</time_frame>
    <description>pharmacokinetic characteristics of Lipovirtide in infected patients：AUC0-t</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 40 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 60 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 80 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lipovirtide Injection</intervention_name>
    <description>Single dosage of Lipovirtide Injection</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female aged from 18 to 60 (include 18 and 60)；&#xD;
&#xD;
          2. Body mass index (BMI) [weight (kg)/ height 2(m2)] is from 18.0 to 26.0（include 18.0&#xD;
             and 26.0），male weight≥50kg，female weight≥45kg；&#xD;
&#xD;
          3. Confirmed HIV-1 infection；&#xD;
&#xD;
          4. HIV viral load ≥ 1000 copies/mL；&#xD;
&#xD;
          5. Patients who have no birth plan within 2 weeks before the screening and 3 months after&#xD;
             the end of the trial, consenting to take effective non-drug contraceptive measures&#xD;
             during the trial period；&#xD;
&#xD;
          6. Understand the purpose of and procedures required for the study and having confirmed&#xD;
             they are willing to participate in the study by signing the informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients in the acute infection stage;&#xD;
&#xD;
          2. Confirmed AIDS patients；&#xD;
&#xD;
          3. Patients who have received antiviral therapy and/or have been vaccinated against HIV；&#xD;
&#xD;
          4. HBsAg is (+), and/or anti-HCV is (+)；&#xD;
&#xD;
          5. Abnormal liver function tests (ALT and / or AST&gt; 3ULN, or total bilirubin&gt; 2ULN)；&#xD;
&#xD;
          6. Glomerular filtration rate &lt;70mL/min/1.73m2, or creatinine ≥ULN；&#xD;
&#xD;
          7. Patients who is currently suffering from a more serious chronic diseases, metabolic&#xD;
             diseases (such as diabetes), neurological and mental diseases；&#xD;
&#xD;
          8. Patients who have previous history of pancreatitis；&#xD;
&#xD;
          9. Females who are pregnant or breastfeeding, or females of childbearing age who are&#xD;
             unable to take contraception as required;&#xD;
&#xD;
         10. Allergic constitution or known allergy to the components of study drug；&#xD;
&#xD;
         11. With a history of smoking addiction within 12 months before screening (average&#xD;
             number≥5 cigarettes per day)；&#xD;
&#xD;
         12. With a history of alcohol abuse within 12 months before screening (average drinking≥14&#xD;
             units of alcohol per week: 1 unit = 285mL beer, 25mL spirits, or 150mL wine) or those&#xD;
             who have a positive alcohol breath test before enrollment；&#xD;
&#xD;
         13. With a history of drug abuse within 12 months before screening or those who tested&#xD;
             positive for addictive substances before enrollment；&#xD;
&#xD;
         14. Patients who have participated in other investigational drug study within 3 months&#xD;
             before screening (except for traditional Chinese medicine）；&#xD;
&#xD;
         15. Other factors that the investigators consider unsuitable for the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haibin Yu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing You'an Hospital, Beijing Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hao Wu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing You'an Hospital, Beijing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liangliang Liu</last_name>
    <phone>+8615386855638</phone>
    <email>lll_xj@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuxian He, Doctor</last_name>
    <phone>+8613126823610</phone>
    <email>yhe@ipbcams.ac.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing You'an Hospital, Beijing Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haibin Yu, MD</last_name>
      <phone>+8613811669802</phone>
      <email>dryuhaibin@ccmu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Hao Wu, MD</last_name>
      <phone>+8613501253203</phone>
      <email>whdoc@sina.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 30, 2020</study_first_submitted>
  <study_first_submitted_qc>October 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

